Ultragenyx Pharmaceutical Inc. (RARE) Earnings Call Transcript
August 4, 2026
Earnings Call Speaker Segments
We've put out a press release that breaks down our financial results, and it's available on our site, ultragenyx.com. On this call with me are Emil Kakkis, who serves as Chief Executive Officer and President, Howard Horn, our Chief Financial Officer, Erik Harris, our Chief Commercial Officer, and Eric Crombez, our Chief Medical Officer. I want to remind all of you that on today's call, forward-looking statements will be made; those statements carry certain risks and uncertainties, and what we actually achieve could differ materially. For details, please see the risk factors covered in our most recent SEC filings. At this point, I'll hand the call over to Emil.
Thanks, Josh, and good afternoon to all of you. During Q2, we kept up our record of solid execution throughout both the development and commercial sides of the business. The commercial organization brought in the largest quarterly revenue the company has ever recorded, and that backs the full-year revenue guidance we've reaffirmed. Just as in earlier quarters, they keep identifying new patients and widening access to Crysvita, DOJOLVI, Evkeeza, and MEPSEVII across the globe. Our commercial and field teams are also getting ready for what could be our first two gene therapy launches, both expected within the next few months. Should they win approval, these two therapies would be the first-ever treatments for diseases where unmet needs are significant and the urgency to treat is high. The PDUFA date for DTX-401 in GSD 1A is only a few weeks off. People living with GSD 1A must drink a cornstarch slurry every few hours, around the clock, day and night, aware that one missed dose might kill them. That serves as a perpetual reminder of their illness and of how severe the consequences of a missed dose can be. In our phase I/II and phase III trials, patients on DTX-401 managed to cut both the amount and the frequency of cornstarch doses substantially, reaching a pre-specified, clinically meaningful degree. Even more important, this gene therapy lets patients achieve a more normal glucose metabolism, remaining within the normal range for a greater portion of the day. Expression of the missing G6Pase enzyme from the DTX-401 vector ought to let their liver break glycogen down into glucose when they are fasting or under metabolic stress. Better glucose regulation has lowered the burden of disease and lessened the chance of a rapid slide into dangerous glucose levels. Moving on now to UX-111. I've spent many years in and around the MPS community, and I've watched so many Sanfilippo patients endure the helplessness of seeing their children decline and die. Sanfilippo syndrome type A carries an urgent need to treat, and yet nothing has existed for these families. Sanfilippo syndrome is a devastating neurodegenerative disease, and these kids lose brain cells daily. Patients aged two to six years gradually lose their cognitive functions. By roughly 10 years old, they're frequently bedridden and tube-fed, going in and out of the hospital for many years. They may become non-responsive for the final five or 10 years and often die as teenagers. Up to now, families have had no choice but to watch helplessly as their children decline and die. According to our clinical data, treating with UX-111 lowers heparan sulfate in these patients and lets them stabilize and preserve cognitive function relative to natural history. Although patients across the study's age range showed benefits after receiving UX-111, it's also evident that treating earlier produced better results by protecting their brains before too much function had been lost. With an illness like Sanfilippo syndrome, no greater urgency to treat exists. The longer you wait, the less function may remain. Dr. Crombez and the development group have been collaborating with regulators globally regarding BLA filings for DTX-401, which targets GSDIa, and UX-111, aimed at Sanfilippo A syndrome. That work involves putting the applications together, answering inquiries for information, and backing inspections of facilities. For one BLA alone, that would be substantial. Right now the team is handling two BLA processes at once, and their PDUFA dates fall just one month apart. Our confidence in what the team is doing to back these filings remains strong. Turning to GTX-102 for Angelman syndrome, the clinical ASO program where we're furthest along. In the phase III ASPIRE study, the final patient enrolled has completed their 48-week visit, and the team is now cleaning and locking the database; with a global study of this kind, that can take months, and we anticipate unblinding and sharing top-line results with you around September or October; given three major catalysts ahead, the second half of 2026 stands to be the most important stretch in our company's history. We're set up to deliver yet another thrilling set of potential firsts for our company, for the communities we serve, and for the wider rare disease medicine field, among them the first gene therapy approvals for Ultragenyx, the first FDA approvals for two devastating and intractable rare diseases, and the first late-stage clinical data in Angelman syndrome. Leading the future of rare disease medicine continues to be a privilege, and we think sustained growth from our existing products, sped up by contributions from possible upcoming launches along with disciplined expense management, offers a clear route to profitability in 2027. I'll hand the call over now to our Chief Commercial Officer, Erik Harris, who will give details on the commercial business and launch readiness activities in the second quarter.
Thanks, and good afternoon to all of you. Like Emil said, we're happy with how consistently and successfully we're executing commercially, and the advantages of our worldwide infrastructure keep showing up across our products and geographies. During the prior call, we explained that while underlying demand for what we sell stays robust, seasonality can introduce fluctuations in revenue from one quarter to the next. During Q2, orders rebounded strongly, exactly as we had anticipated, which strengthens our belief that we will hit the guidance we've set for the entire year. Turning first to Crysvita in North America, where KKC, our partner, handles commercialization, underlying demand keeps expanding at a steady pace. It has been 8 years since launch, and watching new patients steadily begin this therapy remains deeply satisfying. Crysvita's performance in Latin America during Q2 was robust, helped by both ongoing patient expansion and the timing of regional orders, such as those from Brazil and Argentina. Roughly 50 patients started commercial therapy during the quarter, which lifted the region's total patient count on Crysvita to 1,000. As we've noted, ordering patterns will likely keep producing some quarter-to-quarter swings, and we remain confident that underlying demand will keep growing at a steady rate. In Turkey, more than 100 patients are receiving Crysvita via the named patient program. Just as we've seen elsewhere, demand is accelerating as HCPs and patients recognize the advantages this transformative therapy delivers. Moving on to DOJOLVI, the pattern of steady expansion is continuing. In North America, our team produced roughly 30 start forms during the quarter, and roughly 675 patients are now on reimbursed therapy. Across Europe, about 300 patients are receiving treatment through named patient or early access programs, with particularly notable growth in the MENA region after marketing authorization was approved in Kuwait. We also recently started treating DOJOLVI patients in Japan, after it was listed on the National Health Insurance (NHI) Drug Price List. Demand has gotten off to a solid start, which reinforces our view that this country offers yet another meaningful opportunity for growth over time. Evkeeza remains an important and expanding part of our revenue base. Outside the U.S., in our territories, we handle commercialization. More than 500 patients across 25 countries are receiving Evkeeza, while our teams keep working through reimbursement country by country, supporting early access, and transitioning suitable patients onto reimbursed therapy. Past the performance of each individual product, what truly makes this business strong is the scale, reach, and expertise of our worldwide commercial infrastructure. Commercializing rare disease treatments demands deep know-how in each market, spanning patient identification, navigating reimbursement, and execution in the field. That's precisely what our global team delivers every quarter, which gives us strong confidence that we'll be ready for the next possible launches. I'll wrap up with a few brief remarks about the team's efforts to get DTX401 and UX111 launched successfully. Launching 2 gene therapies at the same time is a major endeavor. We're capable of meeting this challenge and prepared to come through for patients. From the very first day, we're making careful, deliberate preparations to serve not just patients and caregivers, but clinicians and payers too. While getting ready for these possible launches, we're working closely with Qualified Treatment Centers, or QTCs, and our contracting and other activities are moving forward on schedule. Their deep involvement, we believe, shows how urgently they feel about patients and families dealing with GSDIa and Sanfilippo syndrome type A, and it reflects their grasp of what our investigational gene therapies could mean clinically. Our market access groundwork is advancing nicely as well, shaped by wide-ranging education and engagement work. Through over 200 interactions with payers, it's been encouraging that they acknowledge the considerable unmet need tied to both diseases and grasp the specific urgency around treating Sanfilippo syndrome. The base needed to enable broad, timely access is in place. Aiming to reduce obstacles for eligible patients once approval comes, we've spent years gearing up for these possible launches. We're prepared to bring these products into our current portfolio and broaden our mission of aiding people with rare disease. Now I'll hand the call over to Howard for further detail on our financial results and guidance.
Thanks, Erik, and good afternoon to all of you. My remarks will cover the financial results we posted for the second quarter, our full-year guidance, and a handful of thoughts about how we intend to reach profitability. Turning first to revenue: for Q2 of 2026, total revenue came in at $214 million. Crysvita accounted for $156 million of that, split between $94 million in North America, $54 million across Latin America and Turkey, and $8 million in Europe — figures that lined up with the quarterly timing and trends Erik described a moment ago. DOJOLVI added $27 million, in line with what we expected for gradual demand growth. Evkeeza brought in $21 million, which works out to 50% growth relative to the second quarter of 2025, as demand keeps climbing after launches in our territories beyond the United States. MEPSEVII delivered $10 million as we keep treating patients in this ultra-rare indication. Operating expenses across the quarter totaled $289 million, a figure that includes $34 million in cost of sales along with $255 million in combined R&D and SG&A. Within total operating expenses, $34 million was non-cash stock-based compensation. The quarter's net loss was $92 million, equal to $0.90 per share. At June 30, cash equivalents plus marketable securities stood at $436 million. Net cash used in operations during the quarter was $97 million — a substantial drop versus the first quarter and in line with what we laid out on our previous call. As our press release noted, we are reaffirming financial guidance for revenue and for combined R&D and SG&A operating expenses. Last, I'd like to offer a few thoughts on how we expect to get to profitability in 2027. Three main factors drive this. One, ongoing double-digit revenue growth from the products we already sell, along with contributions from launches we may soon bring to market. Two, sustained expense discipline and strategic capital allocation in support of those launches, consistent with our operating expense guidance. Three, additional non-dilutive capital to strengthen our balance sheet by monetizing the priority review vouchers tied to DTX401 and UX111, should they be approved. With that, I'll hand the call over to our Chief Medical Officer, Eric Crombez.
Thanks, Howard, and hello everybody this afternoon. I want to begin by discussing GTX-102, also called apazunersen, which is our antisense oligonucleotide being developed to treat Angelman syndrome. Like Emil said — and I'm certain all of you are following this closely — we are getting near the phase III ASPIRE data readout, which we expect sometime in September or October. ASPIRE is a randomized, double-blind, sham-controlled trial that enrolled patients who have a full maternal UBE3A gene deletion, and the criteria we've set for success are clearly defined. Within this 48-week study, the primary statistical alpha is divided between the Bayley-4 cognitive raw score, which gets 80%, and the Multi-Domain Responder Index, or MDRI, which gets 20%. This isn't a hierarchical evaluation, which means the two endpoints get tested in parallel. Should the Bayley cognition endpoint achieve a P value of .04 or lower, or should the MDRI achieve a P value of .01 or lower, then we will have a statistically successful phase III study; we designed and powered this study to hit both endpoints, but achieving statistical significance on both isn't necessary for the study to be considered successful. Throughout the phase I/II program, patients have now received continuous therapy for an average of three years, with the longest nearing five years, and that represents the most significant and mature data set in this field; these patients keep showing meaningful improvements across multiple development domains while their safety profile remains consistent. The phase I/II open-label single-arm data demonstrates substantial clinical benefit well beyond what one might expect from placebo, even though it's an open-label setting. We believe that the long-term experience past the first year of treatment remains even more important as we assess the potential for GTX-102 to deliver meaningful benefit with chronic dosing in the commercial setting. Moving on to UX143, or setrusumab, our monoclonal antibody for treating osteogenesis imperfecta. At the close of last year, we shared results from the phase III ORBIT and COSMIC studies. Although neither study reached statistical significance for the primary endpoints of annualized fracture reductions, we did observe clear signals of biologic activity, statistically meaningful improvements in bone mineral density and patient-reported outcomes, and meaningful reductions in fractures in certain bones and among patients with higher fracture frequencies. Since that time, we've kept analyzing the data and have held discussions with regulators in the U.S. and U.K. Following our discussion with the MHRA, we believe a new randomized study may be required before they would consider reviewing an application for approval. The FDA signaled openness to considering alternative approaches to fracture analysis, and we will need additional conversations with them to further define what additional clinical data would be needed to support a potential BLA. I'll now hand the call back to Emil to provide a reminder of our catalyst for 2026 and some closing remarks.
Thanks, Eric. I want to wrap up by going over a handful of the key catalysts coming in the remainder of this year. You can find the complete list in the corporate deck that's up on our website. First is DTX401, which is for treating Glycogen Storage Disease Type Ia — there we're still working alongside FDA as we head toward our PDUFA action date of August 23rd. Then there's UX111, for treating Sanfilippo syndrome. Much like with DTX401, we're continuing to collaborate with FDA as we approach the PDUFA action date of September 19th. And finally, GTX-102, for treating Angelman syndrome, where we remain on track to report top line phase III data from the ASPIRE study sometime in the September or October timeframe. The second quarter showed once again how strong our global commercial business is, along with our know-how in creating first-ever medicines for patients who have rare diseases. We're prepared for possible launches, we keep executing throughout the portfolio, and we're nearing a group of milestones that might substantially broaden our impact for patients and speed up the next stage of growth for Ultragenyx; so with that, let's get to your questions. Operator, could you please give the Q&A instructions.
Hi there, good afternoon, and congratulations on such a robust quarter. Regarding Angelman syndrome, I was hoping you might give us a bit more background on those endpoints. In particular, has the FDA given the green light on whether just one endpoint would be enough for a filing, and also, what does clinically meaningful actually mean here? I realize both endpoints were powered to succeed, but were they additionally powered to demonstrate results the community would consider clinically acceptable? Thank you.
We spoke with the FDA about sharing of primary alpha, and that was settled during the phase III and pulse conversations regarding the two endpoints. When we talk about sharing of alpha, it means either endpoint may come out positive in their analysis. As for powering, we base it on the effects we have observed. Take a five or six-point change in the Bayley, for instance — we believe that ought to be enough to reach significance, and that six-point level is regarded as clinically meaningful; as for the MDRI, it only produces a score when results are clinically meaningful. In other words, every domain improvement has to cross a threshold of clinical meaningfulness; in that regard, as you recall from phase III, we previously observed roughly two domains net positive that fell within the clinically meaningful range. Given the design, MDRI would only turn out positive when results are clinically meaningful. At this stage, we are comfortable with the two-endpoint approach, and we believe the powering will come out positive alongside clinically meaningful results, according to our plan. We will see the data once they arrive. Thanks, operator. Let's go to the next question.
Thank you very much. Turning to the MDRI endpoint — I believe it has caused a bit of confusion among investors, since as you mentioned, it's the first and the most important secondary, though it's actually a co-primary. It hasn't been used before in Angelman, but you have used it in some of your other MPS disorders. Could you discuss how sensitive it is and whether, given that it's a co-primary, it's a superior endpoint for cognition? Thanks a lot.
Sure. The MDRI method basically picks up efficacy across several domains by applying a clinically meaningful threshold, so that any positive results get captured. What we mean is that among, say, 5 or 6 endpoints, if a patient shows a clinically meaningful change, you count it and then sum all of those clinically meaningful changes. We applied this before in the MEPSEVII program, where it came out significant in our trial of 12 patients. In the analyses we published in our paper, the MDRI was, for instance, 10 times more powerful at detecting change in an enzyme replacement therapy trial than individual endpoints were, correct? That's what we've published previously. We believe it is considerably more sensitive. Looking at the Angelman phase III data, even in the trial of 15 patients, we demonstrate substantial power with P values below 001, even in small studies; it has more power since we capture more efficacy within it. Its sensitivity is quite good, but its meaning matters more, and that's one reason we want it. It isn't only about sensitivity. Being able to show, through 5 important domains, what a drug is doing for a family, I think, is a better assessment of what a drug does in a disease as complex as Angelman, as you know, given that you've worked in the area. We think it's simply a better way of describing things. That said, it is new and it is different, but we're confident in its clinical meaningfulness and its power to detect change in diverse, complex disorders such as Angelman syndrome.
Yeah. Hi there, how's it going? I only wanted to ask, when it comes to the filing plans, will you be filing based on the data that's coming up in September or October? That extra study, plus the extra genotypes, will also back the Angelman's filing. Could you just give a comment on the sequence of operations regarding which data sets are going to be included? Thank you.
Yeah. Thanks, Yigal. What we're going to do about filing hasn't been talked about publicly; that's a matter currently being considered, and right now, we aren't going to lay out what our plan is; we're gathering data across all the types in our program. Our expectation is that we'll secure approval in all the types, but at this point we won't get into what our filing timeline looks like. Thank you.
Okay. Thank you.
Hi there. Congratulations on the quarter, and I appreciate you taking my question.
I'll also ask something about Angelman. I'm curious whether any instances of weakness in the lower extremities or neuroinflammation have come up, based on feedback from the DMC while the study has been running, and how are you framing expectations around that for the top-line readout? Also, what can you share at this point regarding the dropout rate in the phase III?
Yeah. Typically we don't lay out every detail about how the study is run. To be honest, safety and efficacy are going to need to be assessed jointly. At no point has the study been halted or run into any problem while it's been conducted. Things have gone along without interruption up to now, correct? Nothing on the safety side has arisen that would trigger a halt. I'd say we feel good about where things stand. My sense is we don't anticipate a safety profile that differs from what's already been observed, both previously and moving ahead.
Will-
Got it.
Would you like to say anything about the rates of discontinuation that we observed?
Yes. Well, that's not something we would address; at this stage it's also a matter of study conduct. Looking beyond that to the phase III program, there have been very few, and typically it happens closer to the start. For patients who make it, say, past 6, 8, 7, 8 months, we saw those patients persist very well over the long term.
Understood. Thanks very much.
Hi, everyone. I appreciate you taking my question. I have two more about Angelman. To start, what are your current expectations for how the placebo arm will perform on MDRI and the Bayley Cognition score, and how confident are you that a placebo effect won't show up? Next, if you demonstrate a trend on both endpoints without hitting statistical significance, I'm curious how you'd engage with regulators about a possible filing. Thanks.
Sure. We've discussed the placebo effect in the past. In the Bayley Cognition, where we have natural history data as well as randomized data from a separate study, the impact has been 1 point or lower on the Bayley Cognition, so that doesn't shift. To be honest, placebo effects typically don't occur with something like a Bayley score, since the patient isn't aware of what the change ought to be. They can occur when parent input is involved. Here, we believe a placebo effect on the Bayley is unlikely. With the MDRI, we're examining several different endpoints. Some of them could potentially move. That said, we believe the threshold for clinically meaningful change is such that a small amount of change from a bias perspective wouldn't register; a fairly large change is required before scoring occurs. I think that ought to screen out what I'd describe as random placebo changes. Right now, we feel good about both. My view is that a placebo effect wouldn't be a problem. That said, this is neurology, as I always note, and we must always account for the fact that we learn things. We believe the design handles any placebo effect across both endpoints. Thank you.
That's all.
Hi, everyone. Many thanks for taking my question. Emil, might you make your remarks regarding GTX-102 and Bayley a bit clearer? As I recall, you mentioned a change of 5 to 6 points was needed to reach statistical significance versus placebo. I believe this is the first occasion you've actually put a number on that. My assumption is that's a raw score, correct? With GSV, if my memory of your phase III serves me, you demonstrated an effect that was somewhat similar, correct, in phase III. I just wanted to know whether you might clarify those remarks. Thanks a lot.
Yes. I wasn't stating that this is the cutoff for powering. What I was stating is that 5 or 6 points represents a clinically meaningful change, and our power is sufficient to detect that average change. That is what I intended to convey. I did not intend to convey that our power only extends to that cutoff. Our power is more than adequate to detect anything regarded as clinically meaningful within that range. In the data released recently, we stated it was close to a score of 10 when all the data is pooled at 1 year. Should you examine all the different data sets, it falls within that range where we would anticipate the data to be. What I'm conveying is that we have power. Anything we would detect ought to be a clinically meaningful change, and we're confident that we can achieve that.
Excellent. I appreciate you clearing that up.
Excellent. Thanks for fielding our questions, and congratulations on the headway achieved during the quarter. I'll keep things moving regarding GTX-102. I wanted to pose a brief clarifying question about how the alpha is allocated. From what I gather on this call and on more recent ones, you've described having an 80% allocation of alpha toward the Bayley-4 cognition endpoint, with 20% going to MDRI. I was reviewing the press release about completion of enrollment from July of last year, and my recollection is that it indicated a 90/10 alpha allocation. I'm simply wondering whether the statistics shifted between completion of enrollment and the possible readout we're looking at now, and what informed that shift?
Yes. What we intend to do right now is 80/20. 90/10 are quite close. In my view they aren't really meaningfully different. We chose to go with 80/20. No specific date or other rationale drove that. It simply reflected our view of how to divide things between the two. I don't believe it changes things in any meaningful way, though MDRI is extremely powerful; in our estimation 10% or 20% is likely sufficient for it. We had assigned 80%, 90% to the Bayley. When we spoke with FDA, that was the division we had, but they're at ease with what we're putting forward now.
I appreciate the response.
All right. We'll move on to the following one.
Hi there, good afternoon, and thank you for taking my question. To clarify something about setrusumab — I believe during the prepared remarks, you mentioned that the FDA had expressed openness toward options other than the fracture analysis, but that you still need to better define what a BLA would require. Could you clarify that point? Do you believe the existing COSMIC and ORBIT dataset gives you a package that can be filed? And how significant is the open-label extension data currently being generated? Also, when would be the next opportunity to update The Street regarding FDA interactions and the U.S. path forward? Thanks.
Yes. What we were commenting on had to do, essentially, with the kinds of fractures and the kinds of patients involved in terms of the fracture analysis they would be seeking. That said, what we indicated is that, based on our discussions, some further clinical data is going to be needed, and we have to pin down exactly what that entails — that isn't completely pinned down as of yet. At this moment, we can't say whether extension data by itself would suffice, or whether anything beyond that is necessary right now. All right; we're in discussions with them. My sense is that they've shown a lot of willingness to talk through a path forward, and we simply have to develop a solid plan that brings us to a package we can file.
Thanks a lot for fielding my question. I've got another one about Angelman. When it comes to the centralized raters, has there been any decrease in variability within the blinded baseline data, versus what you saw in phase I/II? Thanks.
Personally, we haven't examined that data. We aren't aware of it. At the management level, we don't review the blinded data. That task falls to the team. Our expectation would be that these reviewers — extremely professional and consistent — would assist in lowering overall study variation; that's why it mattered, to keep it in check, to make absolutely certain that a shifting evaluator or a difference in quality and experience across various locations couldn't create an issue. Controlling the endpoint was what we were attempting. At this point, I'm unable to tell you what that effect is. My belief is this is the sort of thing that will help ensure consistency and give us the greatest opportunity for reduced noise in the program. As of right now, we have no data that would let us tell you that.
Thanks a lot.
Hello, everyone. I appreciate you answering my questions. When it comes to the finances, what's your level of comfort with the cash position you currently have, and do you think you might need to raise money in some form? Building on that, if both of your programs — 401 and 111 — get the green light on schedule, how much investment do you expect the forthcoming launches to require? And finally, could you refresh our memory on the potential market size for each of those two indications? Thank you.
Of course. Howard will cover the cash and financing side, and I'll start by addressing the market size question. When it comes to DTX401 for GSDIa, our estimate for the developed, reachable world is roughly 6,000 patients, and that translates to somewhere between 1,500 and 2,000 here in the U.S. As for Sanfilippo syndrome, the global figure sits at 3,000 to 5,000, though within the United States we tend to think of it as 20% or 25% of that number. How large the addressable population ends up being will hinge on the label, but the patients we're focused on are generally more likely to be under 10 than over 10. That's approximately where things stand on population right now. I'll hand it over to Howard to discuss the financials.
Alright, thank you, Tazeen. To begin with the investments, I should probably take everyone back to the guidance we provided covering R&D and SG&A combined; everything there was anchored to either this year or next year compared against 2025. For this year, it came in flat to down low single digits. When we get to 2027, the figure reflects a reduction of no less than 15%. Each of those figures accounted for the launch-related spending we intend to make behind 111 and 401. Additional money is being directed there. Another point worth making is that those programs sit within a sales structure, or bag, that we already have in place. It's a situation with significant leverage, and the investments are targeted. So that covers that portion of the question; turning to cash balance, we disclosed $436 million at the close of the quarter. On the subject of plans for fundraising, monetization of PRVs is where our attention sits. Once approval comes through, we would aim to monetize the DTX401 PRV along with the UX111 PRV.
Hi there, thanks so much. Nice work on the quarter, and nice work on that strong Crysvita figure. I'd like to ask about setrusumab and just follow up on it. I'm just wondering — among the regulatory agencies you've been in discussions with, has any of them signaled they'd be open to using or leaning on bone mineral density as a kind of efficacy determinant? Or is it still the case that they also require efficacy to be shown somehow through fracture rate?
Thank you, Ben. Good question. As things stand, the evidence isn't there yet for BMD's ability to predict fractures the way it exists for osteogenesis — sorry, for osteoporosis, where it's been accepted; we're still at the stage of establishing that. Whether the underlying bone disease is what creates that link is an open question. We've assessed it, and our belief is that it does, but as of now, we're pursuing fracture endpoints of some form as the main pathway to approval rather than relying on BMD. I think we're all in agreement that BMD shows how profoundly active this drug is in these patients. Gaining a full Z-score in a year represents a profound improvement in their bones; that gives us confidence, and my sense is the regulators share confidence that the drug is doing something meaningful. At present, I'd say acceptance of BMD as a primary basis for approval has not yet been enabled.
Hello, I'm Lydia, filling in for Salveen. We really appreciate you answering our question, and congratulations on the advancement. To build on something asked earlier regarding Angelman, about the weakness in the lower extremities, has the FDA given any kind of cutoff for what would be considered acceptable from a safety standpoint, especially when it comes to that lower extremity weakness? Many thanks.
Nothing was given to us in terms of thresholds or limits. Actually, I think during our last discussion — Eric, I'm not certain whether you'd like to add anything here. At least at the end of phase II, we've truly had very little concern, hardly any at all. Eric, what do you think about the FDA? To my knowledge, no limits have been handed to us, nor any figure for how much maximum might be incurred or anything like that.
Correct. In our end of phase II meeting, lower extremity weakness never came up, and like I mentioned, our safety profile stays consistent.
From what we can tell, that problem with them is behind us, and my impression is that things look solid; there haven't been any additional talks.
Hello, everyone. Shelby here, speaking instead of Luca. Perhaps regarding GSDIa: since the PDUFA date is only a few weeks off, might you share any insight into how confident you feel as that choice approaches, and describe the way the assessment has been going? I suppose more precisely, have any requests for information come in from the FDA, and are there any further manufacturing sections that must be resolved prior to the date of the decision? Any details on that would be greatly appreciated. Thank you.
Absolutely. So, indeed, during the evaluation we have received requests for information concerning both CMC and clinical, and we have been responding to those. At this stage we are unable to give an answer while things are in progress. Matters are moving along in that manner; our sense is that the assessment has unfolded as expected, and our sense is that we are positioned well. Even so, we cannot tell you in advance what action the FDA will take. That is theirs to do. Right now, all that we have been engaged in is replying to their inquiries and proceeding in the usual way ahead.
Good afternoon, everybody. Thomas Yip here, filling in for Laura. We have one question. Out of those 300 to 400 Sanfilippo patients who've been identified in the U.S., what number would probably fall inside the age bracket you'd anticipate the label covering and be clinically suitable for treatment? And what is the yearly rate of incidence for newly captured patients? Thank you.
Is it Sanfilippo syndrome you're asking about?
Yes, that is correct. Sanfilippo.
Yeah, I figured Sanfilippo was what you meant. Right. Regarding how common it is — the exact prevalence or how many patients get diagnosed — we have not yet released specific figures. What we do know is that the incidence seems to be roughly 1 in 100,000, which works out to around 30 to 40 newly diagnosed children each year. If you figure that these kids survive into their teens, that gives you some idea of what the prevalent figure might look like, correct? Does that track? In our trial, we have dosed patients who were as old as 8 or 9, I believe. Which age range ends up in the labeling is still unknown, but even among the older patients, we have demonstrated that ambulation, feeding, and communication are stabilized at whatever state they were in when treatment became possible for them. We believe there is a rationale for treating patients at that age, though what the label will say remains uncertain. A substantial group of patients in that age bracket does exist, and we get the sense that there is considerable urgency among them to receive treatment. That at least gives you some flavor of the situation.
Thomas Yip here — got it, and I appreciate you fitting in my question.
thank you. My question about Angelman has 2 parts. During phase I/II, which specific Bayley cognition items or skill clusters seemed to respond most strongly to apazunersen? And are those the very same abilities you anticipate will produce separation in ASPIRE? On a connected note, since ASPIRE's primary endpoint strips out caregiver reporting and asks the child to show abilities within 1 single testing session, how do we weigh the possibility that real gains seen at home won't be fully picked up by the Bayley Cognition assessment?
fine, I'll take the final part first. Caregiver assessments make up a fairly limited portion of the Bayley Cognition, and our endpoint team's view is that at this stage it shouldn't meaningfully influence the raw scores; that doesn't worry us. As for the MDR areas, every area we examined and previously put in our slides is identical to what we're now using. Those 5 domains are Bayley cognition, with a threshold established by the Bayley group. Then there's a communication score — receptive communication on the Bayley. We include a sleep score, plus a behavior scale, the ABC behavior score, and last, a motor score, using either the ASA or the Bayley. That makes 5 domains. These domains are the ones where we observed some meaningful improvement, and they matter to patients. Each one contributes. When you review the earlier descriptions with the heat map we displayed, I believe you can see every endpoint contributing quite substantially. It isn't really any single one that stands out dramatically. Take sleep: some patients show a very large sleep effect since they're kids with severe sleep deprivation. Others without sleep issues may show nothing there. Looking across those endpoints, we observe contributions from every one of them that feeds into the MDRI. No single one is, shall we say, responsible for most of what the MDRI reflects. Time will tell. That's exactly why the MDRI carries such power. When multiple endpoints each contribute, you get considerably more power by capturing efficacy across all areas of patient benefit.
Hello, this is Yi Zhong speaking on behalf of Gavin. We appreciate you addressing our question. I just want to ask something further regarding the Angelman phase I/II trial. It appears that initially 74 patients were enrolled in this study, while the efficacy results we've observed thus far come from the cohort of 40 patients. During the previous quarter, you stated that according to the latest data cut-off, 53 patients have now hit the 12-month milestone. Could you remind us of the timeline for sharing that data? And regarding the efficacy portion specifically, has the data remained consistent with what was seen in the earlier cohort? Thank you.
Sure. So, you're referring to separate cohorts and different time points. It hinges on whether we're discussing the titration group or the expansion group. Those make up the two groups. In our latest release, we discussed every patient who has received therapy, and a few individuals discontinued early during the study. The combined data we shared during the last quarterly call incorporated everyone collectively; we presented on the expansion, which didn't cover everything, but we noted on that last call that the near 10 score across all patients combined for the Bayley cognition represented the most complete dataset having at least a year of treatment. That is part of that data; at this stage we have no plans to release additional phase III data, since we are where we are with the phase III program. I hope that provides some sense of it. What I would say is that as we showed before, for instance, the A and B cohort data, that cohort closely resembles what we're observing and what we believe is in the phase III. Essentially, it comes from the same centers involved in the international study. Right now, we feel confident that what we've learned from phase III has been disclosed to you as a sufficient evaluation of the patients in the countries, and at the sites being used in phase III.
Thanks.
Ahmed here, filling in for Raghuram. Thanks for fielding our questions. Could you share some detail on how prepared you are to launch the upcoming 2 products? What's your view on when the first patient infusions would happen? If the ramp for those products comes in slower than we expect, how much does that affect the 2027 profitability target? Thank you.
All right. I'll start on that, then hand it to Erik for launch readiness, and perhaps you can address profitability. We are fully focused on making sure patients can be treated as quickly as we possibly can, since quite a few patients are truly eager to receive treatment. We're putting things in place for that. Given that we already have 2 products in the inborn errors area, we already have a field team. We're already up and running, and we'll get ready to expand with a more deliberate, stepwise addition. Erik, maybe you can describe our work in the QTCs and how we'll help ensure patients receive infusions as fast as possible.
Sure, I’ll build on what you mentioned — we’ve actually been getting ready for this for several years now, ever since those first filings. When it comes to the institutions and healthcare providers we’ll be reaching out to, there’s roughly a 75% overlap with DOJOLVI and MEPSEVII. Our existing infrastructure can be put to work here, and we grew that infrastructure to handle what our earlier commercial products required. I also want to stress that these will be launches number five and number six for us. Four products have already been launched successfully, so we definitely understand this process, and we’ll be ready. A number of QTCs are already signed, and as we move through our last steps ahead of commercialization, we’ll keep adding to that.
Should be ready to go when we get launched.
We will be. Good.
We are going to be set. Perhaps I should address what you asked regarding how much profitability depends on the launches. You already heard what I said earlier during this call about the various elements that influence profitability; we have not given greater detail about the precise amount that launches contribute, but we do view one as a component of profitability. What matters most to keep in mind, I believe, is that many levers exist for reaching a profitable year, so it is not the case that each launch is essential; that is a lucky position for us, since we have numerous revenue streams and numerous methods for handling how we deploy capital.
Thanks.
Thanks. That wraps up the call for today. Should any further questions come up, feel free to contact us either by phone or at ir@ultragenyx.com. We appreciate your participation.
Thank you. All parties may now disconnect. Have a good day.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Ultragenyx Pharmaceutical Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Ultragenyx Pharmaceutical Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.